Coeliac Centre/First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Istituti Clinici Scientifici Maugeri IRCCS, Gastroenterology Unit of Pavia Institute, University of Pavia, Pavia, Italy.
Br J Nutr. 2020 May 28;123(10):1159-1164. doi: 10.1017/S0007114520000537. Epub 2020 Feb 20.
Follow-up modalities for adult coeliac patients remain controversial. Non-invasive markers to identify coeliac patients on a gluten-free diet (GFD) with persistence of villous atrophy (VA) are still lacking. We aim to develop a score to stratify coeliac patients on a GFD according to their risk of having persistent VA and to tailor follow-up modalities accordingly. The clinical notes of over 700 coeliac patients attending our unit (September 1999-November 2018) were retrospectively examined. A total of 273 patients on a GFD with a histological follow-up performed 12-24 months after diagnosis were selected. We developed a bivariable model based on diet adherence and clinical response evaluated by previously validated methods. A four-level score (0·5, 1·5, 3, 4) was obtained. Patients on a strict GFD and with good clinical conditions (score 4) have a very low risk of persistence of VA (2 (95 % CI 1, 5) %). Conversely, the risk is very high (46 (95 % CI 25, 68) %) in patients with poor adherence to a GFD and unsatisfactory clinical response (score 0·5). A score of 1·5 (poor GFD adherence and persistent well-being) is linked with a high risk (23 (95 % CI 14, 36) %). Risk is intermediate (6 (95 % CI 3, 10) %) in patients scoring 3 (strict GFD and no/partial clinical improvement). Three patients who developed complications belonged to this scenario. Patients at low risk of persistent VA can be followed-up non-invasively, whereas a biopsy should be repeated in those at high/very high risk. Case-by-case evaluation is needed in patients at intermediate risk. Studies on a larger sample size are required to confirm these data.
成人乳糜泻患者的随访方式仍存在争议。目前仍缺乏非侵入性标志物来识别接受无麸质饮食(GFD)治疗但绒毛萎缩(VA)持续存在的乳糜泻患者。我们旨在开发一种评分系统,根据GFD 患者 VA 持续存在的风险对其进行分层,并相应地调整随访方式。回顾性检查了我院(1999 年 9 月至 2018 年 11 月)就诊的 700 多名乳糜泻患者的临床记录。选择了 273 名接受 GFD 治疗且在诊断后 12-24 个月进行组织学随访的患者。我们基于饮食依从性和通过先前验证的方法评估的临床反应开发了一个双变量模型。获得了一个四级评分(0·5、1·5、3、4)。严格遵循 GFD 且临床状况良好(评分 4)的患者 VA 持续存在的风险非常低(2(95 % CI 1,5) %)。相反,依从性差且临床反应不佳(评分 0·5)的患者风险非常高(46(95 % CI 25,68) %)。饮食依从性差且持续存在不适(评分 1·5)与高风险相关(23(95 % CI 14,36) %)。评分 3(严格遵循 GFD 且无/部分临床改善)的患者风险处于中间水平(6(95 % CI 3,10) %)。在这一方案中,有 3 名患者发生了并发症。VA 持续存在风险低的患者可以进行非侵入性随访,而高/极高风险的患者则需要重复进行活检。对于风险处于中间水平的患者,需要进行个案评估。需要进行更大样本量的研究来验证这些数据。